

The one into two at 10

January 2013 brought a clear safety and dose signal in the BI-505 Phase I for relapsed and refractory multiple myeloma (MM). In preclinical studies, BI-505 showed a tumour cell killing effect possibly by making myeloma cells susceptible to apoptosis. The Phase I was dose escalating with a safety end point. Interestingly but anecdotally, seven of 29 patients (24%) on extended dosing showed stable disease. BI-505 will progress to a small Phase IIa during 2013. BioInvent intends to partner BI-505 either with Phase II efficacy data or sooner if a lucrative Phase I deal can be achieved.

Year end	Revenue (SEKm)	PBT* (SEKm)	EPS* (SEK)	DPS (SEK)	P/E (x)	Yield (%)
12/10	83	(124)	(2.1)	0.0	N/A	N/A
12/11	125	(67)	(1.0)	0.0	N/A	N/A
12/12e	45	(148)	(1.9)	0.0	N/A	N/A
12/13e	45	(29)	(0.4)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding intangible amortisation and exceptional items.

The one: BI-505 is crucial to current value

BI-505 is the remaining clinical programme from the January 2012 portfolio. Hence, gaining maximum value is important for investors. A deal by GenMab in August 2012 with J&J on a Phase I MM antibody, daratumumab, shows possible value. GenMab, a larger company, gained \$55m upfront and \$88m in equity with milestones and a 10%+ royalty. However, such Phase I deals are infrequent and BioInvent investors need to be prepared to fund BI-505 to add value by generating Phase II efficacy data.

Into two at 10: BI-505 progression to Phase II

BI-505 blocks the function of the cell surface adhesion molecule ICAM-1 (CD54). In the cancer literature, myeloid cells show cell-adhesion mediated drug resistance if attached to other cells. In BioInvent's patent [EP 2468775](#) (priority December 2006), ICAM blocking is claimed to cause apoptosis (cell suicide). The 35-patient dose escalation [study](#) in relapsed and refractory MM tested 11 dose stages of 0.0004mg/kg to 20mg/kg. BI-505 at 10mg/kg saturated the ICAM sites on bone marrow myeloma cells; this dose will be used for Phase II. Stable disease (based on M protein biomarker levels) was seen in 24% of the 29 patients who received extended dosing over 0.06mg/kg (level 6). The likelihood of success remains at 30%.

Valuation: Cash conservation to rebuild the portfolio

BioInvent had Q3 ytd cash of SEK153m with revenues of SEK 34m. Estimating year-end 2012 cash is difficult due to the actual H212 restructuring costs; SEK25-40m seems a probable range. The company needs to invest in BI-505, bring forward two other candidates into Phase I and support n-CoDeR. Operating cash costs in 2013 should be SEK75m. The small Phase IIa BI-505 study due to start sometime in 2013 will be inexpensive; a broader Phase IIb may eventually follow. Collaborations may generate milestones in 2013 if partners designate clinical candidates. This could give funding into 2014 before any BI-505 deal value, if partnered in 2013.

Pharma & biotech

4 February 2013

Price SEK3.55

Market cap SEK262m

Shares in issue 73.93m

Code BINV

Primary exchange OMX Stockholm

Share price performance



% 1m 3m 12m

Abs 1.2 31.5 (82.9)

Rel (local) (4.8) 18.8 (84.4)

52-week high/low SEK20.4 SEK1.8

Business description

BioInvent is a human therapeutic antibody company based in Lund in southern Sweden. It has an innovative cancer antibody, BI-505 for multiple myeloma entering Phase II, plus the n-CoDeR antibody library and various research collaborations that generate some income.

Next events

FY12 results 21 February 2013

Analysts

Dr John Savin MBA +44(0)20 3077 5735

Robin Davison +44(0)20 3077 5737

healthcare@edisoninvestmentresearch.co.uk

[Edison profile page](#)

Exhibit 1: Financial summary

SEKm	2010	2011	2012e	2013e
31-December	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS				
Revenue	83	125	45	45
Cost of Sales	0	0	0	0
Gross Profit	83	125	45	45
EBITDA	(135)	(66)	(147)	(24)
Operating Profit (before amort and except)	(125)	(72)	(153)	(30)
Intangible Amortisation	3	0	0	0
Restructuring and provisions	(1)	0	(48)	0
Other	0	0	9	0
Operating Profit	(124)	(72)	(192)	(30)
Net Interest	1	5	5	1
Profit Before Tax (norm)	(124)	(67)	(148)	(29)
Profit Before Tax (FRS 3)	(123)	(67)	(187)	(29)
Tax	0	0	0	0
Profit After Tax (norm)	(126)	(67)	(139)	(29)
Profit After Tax (FRS 3)	(123)	(67)	(187)	(29)
Average Number of Shares Outstanding (m)	60.5	67.2	72.2	73.9
EPS - normalised (ore)	(2.08)	(1.00)	(1.92)	(0.39)
EPS - normalised fully diluted (ore)	(2.08)	(1.00)	(1.92)	(0.39)
EPS - (IFRS) (ore)	(2.04)	(1.00)	(2.59)	(0.39)
Dividend per share (c)	0.0	0.0	0.0	0.0
Gross Margin (%)	100.0	100.0	100.0	100.0
EBITDA Margin (%)	N/A	N/A	N/A	N/A
Operating Margin (before GW and except) (%)	N/A	N/A	N/A	N/A
BALANCE SHEET				
Fixed Assets	14	12	10	9
Intangible Assets	3	0	0	0
Tangible Assets	10	11	10	8
Investments	1	1	1	1
Current Assets	124	193	47	23
Stocks	1	0	0	0
Debtors	12	19	16	16
Cash	106	174	31	7
Other	5	0	0	0
Current Liabilities	(64)	(68)	(20)	(20)
Creditors	(64)	(68)	(20)	(20)
Short term borrowings	0	0	0	0
Long Term Liabilities	0	0	0	0
Long term borrowings	0	0	0	0
Other long term liabilities	0	0	0	0
Net Assets	74	137	37	12
CASH FLOW				
Operating Cash Flow	(118)	(60)	(241)	(20)
Net Interest	1	5	5	1
Tax	0	0	0	0
Capex	(5)	(5)	(5)	(5)
Acquisitions/disposals	0	0	0	0
Financing	144	128	97	0
Dividends	0	0	0	0
Net Cash Flow	22	68	(143)	(24)
Opening net debt/(cash)	(84)	(106)	(174)	(31)
HP finance leases initiated	0	0	0	0
Other	0	0	0	0
Closing net debt/(cash)	(106)	(174)	(31)	(7)

Source: Edison Investment research, Biolvent International

EDISON INVESTMENT RESEARCH LIMITED

Edison Investment Research Limited (Edison) is a leading international investment research company. Edison and its subsidiaries (Edison Group) have won industry recognition, with awards both in Europe and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison's research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York, Sydney and Wellington. Edison is authorised and regulated by the United Kingdom's Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only.

DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been commissioned by EMED Mining and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c)(1)(a), (b) and (c) of the FAA). It is not intended for retail clients. This is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct an investment business and, accordingly, does not hold any positions in the securities mentioned in this report. However, their respective directors, officers, employees and contractors may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication.

Registered in England, number 4794244, Edison Investment Research Limited is authorised and regulated by the United Kingdom Financial Services Authority. www.edisoninvestmentresearch.co.uk. Registered on the New Zealand Financial Service Providers Register, number 247505, Edison Investment Research (NZ) Limited is registered to provide wholesale and/or generic financial adviser services and is regulated by the New Zealand Financial Markets Authority.

London +44 (0)20 3077 5700
Lincoln House, 296-302 High
Holborn, London, WC1V 7JH, UK

New York +1 212 551 1118
380 Lexington Avenue, Suite 1724
NY 10168, New York, US

Wellington +64 4894 8555
Level 15 HP Tower, 171 Featherston
Street, Wellington 6011, NZ

Sydney +61 (0)2 9258 1162
Level 33, Australia Square, 264 George St,
Sydney, NSW 2000, Australia